TME Pharma N.V. reported earnings results for the half year ended June 30, 2025. For the half year, the company reported sales was EUR 0.027 million. Net loss was EUR 2.1 million compared to EUR 3.25 million a year ago.

Basic loss per share from continuing operations was EUR 0.02 compared to EUR 0.12 a year ago.